Recombinant Human CD52 Protein，His

CD52 is a small glycoprotein predominantly expressed on the surface of lymphocytes, including T and B cells, and is involved in immune regulation. The research surrounding CD52 has gained significant attention due to its potential implications in therapeutic interventions for various autoimmune diseases and hematological malignancies. One of the notable developments in this field has been the creation of recombinant forms of CD52, which serve as crucial tools for understanding its biological function and for therapeutic applications. For instance, the humanized monoclonal antibody alemtuzumab, which targets CD52, has been successfully used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis (MS). Studies have demonstrated that CD52 interacts with various immune cells, leading to the depletion of T and B lymphocytes, enhancing the understanding of the mechanisms underlying immune system modulation. Furthermore, the exploration of CD52 as a potential target for immunotherapy has opened new avenues for research, especially in creating novel treatments that leverage CD52's expression patterns to selectively target diseased cells while preserving healthy tissues. Overall, the ongoing research into CD52 recombinant proteins not only contributes to the fundamental knowledge of immune cell biology but also holds promise for innovative therapeutic strategies in both oncology and autoimmune disorders.